MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-20-2023
Acer Therapeutics ROE Ratio 2011-2026 | ACER
Annual ROE Ratio Acer Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 156.54 | 891.97 | -278.27 | -160.14 | -47.2 | -63.55 | -294.9 | -125.0 | -202.34 | -80.95 | -309.74 | -82.95 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 891.97 | -309.74 | -49.71 |
Quarterly ROE Ratio Acer Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 158.55 | 168.71 | 174.74 | 162.25 | 11.03 | -181.2 | -275.01 | -277.73 | -349.82 | -270.68 | -277.4 | -202.42 | -231.01 | -187.51 | -177.45 | -132.07 | -140.87 | -121.08 | -71.7 | -28.36 | -43.93 | -50.71 | -53.96 | -44.68 | -26.17 | 7.91 | -55.89 | -139.11 | -168.16 | -215.73 | -167.01 | -92.97 | -145.1 | -168.17 | -195.07 | -157.23 | -185.05 | -160.74 | -119.33 | -62.68 | -144.45 | -198.41 | -258.92 | -239.18 | -257.21 | -193.47 | -139.05 | -56.86 | -18.03 | -20.66 | -18.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 174.74 | -349.82 | -118.38 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Graybug Vision
GRAY
|
445.14 | - | -11.23 % | $ 9.65 M |  USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | $ 20.16 | -2.61 % | $ 2.54 B | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.79 | -6.17 % | $ 4.31 M |  China |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.71 | -2.88 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 164.05 | -1.4 % | $ 8.16 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
149.7 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.55 | -2.06 % | $ 1.39 B | Britain |
 |
BridgeBio Pharma
BBIO
|
35.13 | $ 64.53 | -1.48 % | $ 12.4 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-231.16 | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 58.53 | -2.03 % | $ 11.2 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-67.58 | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
94.87 | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
529.06 | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-79.41 | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
515.73 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
515.73 | - | -4.36 % | $ 27 M | USA |
 |
Cabaletta Bio
CABA
|
-28.65 | $ 3.25 | -1.52 % | $ 3.8 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-55.55 | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Capricor Therapeutics
CAPR
|
-98.61 | $ 25.84 | -3.8 % | $ 692 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
-97.53 | $ 0.98 | -3.92 % | $ 71.9 M | USA |
 |
Certara
CERT
|
-0.15 | $ 7.24 | 2.7 % | $ 1.16 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-151.03 | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
-79.66 | - | 7.55 % | $ 38.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Coherus BioSciences
CHRS
|
122.99 | $ 1.65 | - | $ 155 M | USA |
 |
Evelo Biosciences
EVLO
|
2294.21 | - | -14.46 % | $ 27.9 M | USA |